HC Wainwright Analysts Boost Earnings Estimates for SABS

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Analysts at HC Wainwright boosted their Q1 2025 earnings estimates for SAB Biotherapeutics in a research note issued on Tuesday, April 1st. HC Wainwright analyst E. White now forecasts that the company will post earnings of ($1.14) per share for the quarter, up from their previous forecast of ($1.35). HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q2 2025 earnings at ($1.12) EPS, Q3 2025 earnings at ($1.14) EPS, Q4 2025 earnings at ($1.18) EPS, FY2025 earnings at ($4.59) EPS, FY2026 earnings at ($3.59) EPS and FY2027 earnings at ($2.97) EPS.

SAB Biotherapeutics (NASDAQ:SABS) last announced its earnings results on Friday, March 28th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.07). The company had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.12 million. SAB Biotherapeutics had a negative return on equity of 94.37% and a negative net margin of 1,450.14%.

Separately, Chardan Capital decreased their price objective on SAB Biotherapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, SAB Biotherapeutics presently has a consensus rating of “Buy” and a consensus target price of $11.40.

SAB Biotherapeutics Stock Performance

Shares of SABS stock opened at $1.25 on Thursday. The business has a 50-day moving average price of $1.89 and a two-hundred day moving average price of $2.81. SAB Biotherapeutics has a 12-month low of $1.11 and a 12-month high of $5.01. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.09.

Institutional Trading of SAB Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Northern Trust Corp purchased a new position in shares of SAB Biotherapeutics in the fourth quarter worth about $43,000. Kovitz Investment Group Partners LLC bought a new position in SAB Biotherapeutics during the 3rd quarter worth approximately $52,000. Diadema Partners LP purchased a new position in SAB Biotherapeutics in the 4th quarter worth approximately $114,000. Geode Capital Management LLC lifted its position in SAB Biotherapeutics by 18.8% in the fourth quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock valued at $307,000 after purchasing an additional 12,692 shares during the last quarter. Finally, HB Wealth Management LLC boosted its stake in shares of SAB Biotherapeutics by 118.6% during the fourth quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock valued at $982,000 after purchasing an additional 128,800 shares during the period. 7.82% of the stock is currently owned by hedge funds and other institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.